Precision biosciences inc (DTIL)
CashFlow / Yearly
Dec'19Dec'18
Cash flows from operating activities:
Net loss

-92,877

-46,037

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

5,317

2,354

Share-based compensation

8,940

2,453

Loss on disposal of property, equipment, and software

-22

-14

Non-cash interest expense

182

-

Change in fair value of convertible notes payable

9,758

-

Changes in operating assets and liabilities:
Prepaid expenses

584

7,476

Accounts receivable

441

523

Other assets and other current assets

-1,032

448

Accounts payable

667

-673

Accrued other expenses and other current liabilities

4,835

1,790

Deferred revenue

-7,866

-3,177

Net cash used in operating activities

-71,015

-51,723

Cash flows from investing activities:
Acquisition of license rights

-

1,400

Purchases of property, equipment and software

24,666

14,278

Proceeds from disposal of property, equipment, and software

-

15

Net cash used in investing activities

-24,666

-15,663

Cash flows from financing activities:
Proceeds from stock option exercises

1,261

171

Issuance of Series B convertible preferred stock, net of issuance costs

-

109,742

Deferred offering costs

2,622

2,136

Issuance of convertible notes

39,550

-

Proceeds from IPO, net of underwriting discounts and commissions

135,185

-

Net cash provided by financing activities

173,374

107,777

Net increase (decrease) in cash and cash equivalents

77,693

40,391

Supplemental disclosures of noncash financing and investing activities:
Common stock issued on conversion of convertible notes payable

49,490

-

Property, equipment and software additions included in accounts payable, accrued expenses and other current liabilities

401

1,340

Deferred offering costs included in accounts payable, accrued expenses and other current liabilities

168

406